Positive results from early trial of drug that could protect brain cells
Date
Research news
Date
The first participant has been recruited to a pioneering clinical trial which is testing a new drug called NLX-112 to investigate its potential for people with Parkinson’s.
Date
UCB, a global pharmaceutical company, has joined forces with Parkinson's UK, and the Parkinson's Foundation in the US, to establish a Patient Engagement Council for Parkinson's Research.
Date
We’ve developed an interactive communications toolkit to help researchers in all areas of health research to keep in touch with their participants. It is supported by the Health Research Authority (HRA) as part of the Make It Public strategy.
Date
Results show that atomoxetine, a drug used to treat attention deficit hyperactivity disorder (ADHD), could improve thinking and impulsiveness in Parkinson’s.
Date
Researchers in the United States have shown that a compound found in fruit - farnesol - has the potential to play a protective role to dopamine-producing brain cells.
Date
New research has been published that sheds an important light on how the production of a key protein in the brain is controlled This could pave the way for new treatments for a wide range of neurological conditions.
Date
Research shows it’s possible to identify Parkinson’s based on compounds found on the surface of skin. The findings offer hope that the condition could be diagnosed through a simple swab test.
Date
We’re investing up to £1.2m into pioneering research in partnership with the University of Sheffield, which aims to develop a drug to protect dopamine-producing brain cells.
Date
The earlier groundbreaking clinical trial proved inconclusive. So we’re launching a new company tasked with planning a possible new trial.
Date
New research has advanced our understanding of a protein called alpha-synuclein, which is believed to play a central role in damaging brain cells in Parkinson’s.